The absence of risks and side effects have since its inception in November 2000 as on drawn after an excellent positioning of the company led to and positively its financial development. Stem cells of human origin produced legally and ethically justifiable are ethical dimension of research by axioGENESIS the main advantage of this technology. Removed skin cells or blood cells of a patient in a State to move, which is equipped with a cellular development potential, no concern raises individually and socially. Goal is to cure, re programmed skin cells or blood cells evolve into heart cells, which bring about healing in the heart attack-related damage to the heart muscle tissue. Corporate information the Axiogenesis AG was founded in November 2000 as a spin-off of the University of Cologne, headquartered in Cologne, Germany.
Dr. Heribert Bohlen, the founder and CEO of Axiogenesis AG, Dr. Bernd belong to the management Fronhoff, CFO and COO of Axiogenesis AG, on. The company has 24 employees, of which 19 scientifically active employees. The Axiogenesis AG, Roche applied sciences to the development of the equipment of the xCELLigence and since 2009 with TuV international TuV Rheinland Japan has been cooperating since 2008. Since 2010, the products and services exclusively by Lonza Cologne AG are sold. 2010 a license agreement signed with the University of Kyoto to use the iPS technology developed by Professor Yamanaka. Although you can save money purchasing erectile dysfunction medications from from uk viagra deeprootsmag.org an online pharmacy. Most generic levitra online are totally unaware they are suffering from a medical condition called Phimosis. Research done on the side effects of this ED drug shows that it has some negative lowest price for cialis deeprootsmag.org and some positive side effects. Since its introduction in the global markets in 1998, it has been one of the most cheap online levitra http://deeprootsmag.org/2019/03/12/pushing-the-envelope-of-nordic-jazz/ selling prescription medicines. Thus, the Axiogenesis AG is the first European company that owns one such license.
Description of the company the Managing Director of V + Management GmbH Michael Vogel in Cologne is devoted to since 2002 successfully the focus of venture capital / private equity. Specialists at the University of Munich with completion of 2005-2006 equipped him his training to the venture capital, to impose 18 ventures so far by three fund companies. This positive development of the previous V + fund companies puts the V + GmbH & co. Fund, 3 KG in conjunction with the Uwe Kerner from Dresden, Advisory Board members and partners Chartered Accountants continued. Private investors should invest in the German economy out of pure self-interest and thus creating a foundation for ideas and innovation. According to the V + invests philosophy “Give money sense!”, the V + GmbH & co. funds 3 KG the investor money in the area of “Direct investments” only after the imposed herself on V + ethics INDEX. According to this index the V + participation principle aims, primarily companies to participate in, which stand out with their product or their technology as far as possible from other companies. The target companies have their headquarters, primarily in Germany, Austria or of Switzerland. This is complemented by an ethically reasonable business purpose in terms of products, services, or inventions from sections, which can improve the world and offer understandable added value the people in our society. Company contact: V + Management GmbH Michael Vogel Wuppertal 7 51061 Cologne Tel: 0221 9649 0217 E-Mail: Web: PR contact: press distribution list public Effect Hans Kolpak Gohren 2 95493 Bischofsgrun Tel: 09276 926 9711 E-Mail: Web: